GNTA
Genenta Science S.p.A.
$1.87
-2.60%
$90.2M
No data for this timeframe.
Vol
Market Cap$90.2M
Cap SizeMicro Cap
Inst. Holders3 funds
Inst. Value$192.5K
Inst. Activity0 buys / 1 sells
Reddit Sentiment44° Neutral
SEC Reports3
Press Releases2
Exchange Nasdaq·Sector Biological Products, (No Diagnostic Substances)·Inc. L6·CIK 0001838716·Prev Close $1.92
Recent Activity
Jun 5, 2026
SEC
Genenta Science completed the acquisition of the remaining 80.5% of A.T.C. S.r.l. for €9.6M, paid via the issuance of 24
6-K — Impact 6/10
Jun 1, 2026
short_volume
Short Volume: GNTA — 58.7% short (5.2M / 8.8M)
Short: 5,190,756 | Exempt: 48,019 | TRF Vol: 8,841,669 | Short Ratio: 58.7% | Off-exchange volume (d
Apr 23, 2026
SEC
Genenta Science (GNTA) has entered into a definitive agreement to acquire a 19.9% stake in Sophia High Tech, an Italian
6-K — Impact 7/10
Apr 14, 2026
SEC
Genenta Science received a Nasdaq deficiency letter due to its stock trading below $1 for 30 consecutive days, triggerin
6-K — Impact 7/10
Mar 30, 2026
Insider
Paracchi Pierluigi was granted 100,000 shares
Chief Executive Officer
Mar 30, 2026
Insider
Galimi Francesco was granted 20,000 shares
CMO& Head of Development
Mar 30, 2026
Insider
SLANSKY RICHARD B was granted 80,000 shares
Chief Financial Officer
Inst.
MORGAN STANLEY — TRIM
15,420 shares ($10.4K)
Price Targets
Historical data — last covering-analyst action Oct 2024. No current recommendation available.
$6.98 (Oct 2024)
Current $0.7082
Low $6.98
Median $6.98
High $6.98
1 analysts
$6.98
$6.98
Analyst Ratings
2Strong Buy
4Buy
1Hold
0Sell
0Strong Sell
Historical Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Oct 2, 2024 | HC Wainwright & Co. | REITERATE | Buy → Buy |
| May 13, 2024 | HC Wainwright & Co. | REITERATE | Buy → Buy |
| Feb 8, 2023 | HC Wainwright & Co. | REITERATE | Buy |
| Jan 5, 2023 | EF Hutton | INITIATE | Buy |
| Jul 25, 2022 | HC Wainwright & Co. | INITIATE | Buy |
Latest Reports
MIXED
6-K
6/10
Genenta Science completed the acquisition of the remaining 80.5% of A.T.C. S.r.l. for €9.6M, paid via the issuance of 24
Jun 5, 2026
BULLISH
6-K
7/10
Genenta Science (GNTA) has entered into a definitive agreement to acquire a 19.9% stake in Sophia High Tech, an Italian
Apr 23, 2026
BULLISH
Press
8/10
Genenta Science (GNTA) announced a binding offer to acquire Italian aerospace and defense manufacturer Sòphia High Tech
Mar 27, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| ALLIANZ SE | $157.3K | DOUBLED |
| Independent Advisor Alliance | $24.9K | — |
| MORGAN STANLEY | $10.4K | TRIM |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| Mar 30, 2026 | Paracchi Pierluigi | A | $0.00 |
| Mar 30, 2026 | Galimi Francesco | A | $0.00 |
| Mar 30, 2026 | SLANSKY RICHARD | A | $0.00 |
| Mar 30, 2026 | Mutti Miguel | A | $0.00 |
| Mar 30, 2026 | PARACCHI GIACOMOANTONIO | A | $0.00 |
Reddit Sentiment
44°
Neutral
Bearish
Neutral
Bullish
3 institutional holders with $192.5K total value (286,506 shares) as of 2026-Q1. Top holders: ALLIANZ, Independent, MORGAN. Net selling activity: 1 institutions trimmed/exited vs 0 added.
Top Institutional Holders — 2026-Q1
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | ALLIANZ SE | 234,050 | $157.3K | 81.7% | DOUBLED +126.2% |
| 2 | Independent Advisor Alliance | 37,036 | $24.9K | 12.9% | — |
| 3 | MORGAN STANLEY | 15,420 | $10.4K | 5.4% | TRIM -66.4% |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| MORGAN STANLEY | TRIM | 45,900 | 15,420 | -66.4% | $10.4K | 2026-Q1 |
| MORGAN STANLEY | DOUBLED | 2,200 | 45,900 | +1986.4% | $68.4K | 2025-Q4 |
| ALLIANZ SE | DOUBLED | 103,250 | 233,550 | +126.2% | $927.2K | 2025-Q1 |
6 unique insiders with 6 transactions. Net insider value: $0.00 ($0.00 bought, $0.00 sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Mar 30, 2026 | Paracchi Pierluigi | Chief Executive Officer | AWARD | 100,000 | — | — |
| Mar 30, 2026 | Galimi Francesco | CMO& Head of Development | AWARD | 20,000 | — | — |
| Mar 30, 2026 | SLANSKY RICHARD B | Chief Financial Officer | AWARD | 80,000 | — | — |
| Mar 30, 2026 | Mutti Miguel Maria | Director | AWARD | 20,000 | — | — |
| Mar 30, 2026 | PARACCHI GIACOMOANTONIO | Director | AWARD | 20,000 | — | — |
| Mar 30, 2026 | Sharei Armon | Director | AWARD | 20,000 | — | — |
3 SEC filing reports analyzed. Sentiment: 1 bullish, 1 bearish, 1 mixed, 0 neutral. Avg impact: 6.7/10.
MIXED
6-K
6/10
Genenta Science completed the acquisition of the remaining 80.5% of A.T.C. S.r.l. for €9.6M, paid vi
Jun 5, 2026
BULLISH
6-K
7/10
Genenta Science (GNTA) has entered into a definitive agreement to acquire a 19.9% stake in Sophia Hi
Apr 23, 2026
BEARISH
6-K
7/10
Genenta Science received a Nasdaq deficiency letter due to its stock trading below $1 for 30 consecu
Apr 14, 2026
Historical analyst distribution (last covering-analyst action Oct 2024): 86% buy across 7 analysts — 2 strong buy, 4 buy, 1 hold, 0 sell, 0 strong sell. No current recommendation available.
Analyst Price Targets
Historical data — last covering-analyst action Oct 2024. No current recommendation available.
$6.98 mean target (Oct 2024)
$6.98 Low
$6.98 High
| Metric | Value |
|---|---|
| Current Price | $0.7082 |
| Target Low | $6.98 |
| Target Mean | $6.98 |
| Target Median | $6.98 |
| Target High | $6.98 |
| # Analysts | 1 |
| Recommendation | — (no recent coverage) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q | $0.00 | $0.00 | $0.00 | — | — | — | $0.0B | — | — |
| Next Q | $0.00 | $0.00 | $0.00 | — | — | — | $0.0B | — | — |
| Current FY 2026-12-31 |
$0.00 | $0.00 | $0.00 | — | — | — | $0.0B | — | — |
| Next FY | $0.00 | $0.00 | $0.00 | — | — | — | $0.0B | — | — |
3 analyst firms have rated this stock: 0 upgrades, 0 downgrades, 3 initiations.
Historical Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| Oct 2, 2024 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| May 13, 2024 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| Feb 8, 2023 | HC Wainwright & Co. | REITERATE | — | Buy |
| Jan 5, 2023 | EF Hutton | INITIATE | — | Buy |
| Jul 25, 2022 | HC Wainwright & Co. | INITIATE | — | Buy |
| Jan 13, 2022 | Maxim Group | INITIATE | — | Buy |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 2 | 4 | 1 | 0 | 0 | 86% | |
| May 1, 2026 | 2 | 4 | 1 | 0 | 0 | 86% | |
| Apr 1, 2026 | 2 | 4 | 1 | 0 | 0 | 86% | |
| Mar 1, 2026 | 2 | 4 | 1 | 0 | 0 | 86% | |
| Feb 1, 2026 | 2 | 4 | 1 | 0 | 0 | 86% | |
| Jan 1, 2026 | 2 | 4 | 1 | 0 | 0 | 86% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
44°
Neutral
Bearish
Neutral
Bullish
5 mentions
2 bullish
3 bearish
5 time periods
Reddit Sentiment History
| Date | Mentions | Sentiment | Bullish | Bearish | Threads |
|---|---|---|---|---|---|
| May 12, 2026 | 1 | 40° Cool | 0 | 1 | 1 |
| May 12, 2026 | 1 | 40° Cool | 0 | 1 | 1 |
| May 12, 2026 | 1 | 40° Cool | 0 | 1 | 1 |
| Mar 24, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
| Mar 24, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
Recent Reddit Threads
GNTA - Genenta Science
▲ 1
💬 1
⚡ 0.3
GNTA - Genenta Science
▲ 1
💬 1
⚡ 0.1
Jun 12, 2026
Clinical Trial
A Study Evaluating Temferon in Patients With Glioblastoma & Unmethylated MGMT
Phase Phase 2 — TERMINATED
Jun 1, 2026
short_volume
Short Volume: GNTA — 58.7% short (5.2M / 8.8M)
Short: 5,190,756 | Exempt: 48,019 | TRF Vol: 8,841,669 | Short Ratio: 58.7% | Off-exchange volume (dark pool + OTC)
Apr 23, 2026
other
Genenta signs Definitive Agreements with Sophia High Tech
Genenta signs Definitive Agreements with Sophia High Tech
Genenta enters aerospace as it continues its strategic transformation into a next-generation
Apr 14, 2026
clinical_trial_readout
T-90d Trial Readout: Temferon (Phase 2)
Trial: A Study Evaluating Temferon in Patients With Glioblastoma & Unmethylated MGMT
Sponsor: Genenta Science
Phase: Phase 2 | Status: ACTIVE_NOT_RECR
Apr 6, 2026
clinical_trial_readout
T-90d Trial Readout: Temferon (Phase 2)
Trial: A Study Evaluating Temferon in Patients With Glioblastoma & Unmethylated MGMT
Sponsor: Genenta Science
Phase: Phase 2 | Status: ACTIVE_NOT_RECR
Apr 1, 2026
clinical_trial_readout
T-90d Trial Readout: Temferon (Phase 2)
Trial: A Study Evaluating Temferon in Patients With Glioblastoma & Unmethylated MGMT
Sponsor: Genenta Science
Phase: Phase 2 | Status: ACTIVE_NOT_RECR
Apr 1, 2026
clinical_trial_readout
T-90d Trial Readout: Temferon (Phase 2)
Trial: A Study Evaluating Temferon in Patients With Glioblastoma & Unmethylated MGMT
Sponsor: Genenta Science
Phase: Phase 2 | Status: ACTIVE_NOT_RECR
Mar 27, 2026
contract
Genenta, evolving into Saentra Forge, has signed a Binding Offer with Sòphia High Tech, an Italian company manufacturing critical parts for Europe's space and defense programs
Genenta has signed a Binding Offer with Sòphia High Tech, an Italian company manufacturing critical parts for Europe's space and defense programs
Mar 24, 2026
other
Genenta, evolving into Saentra Forge, continues to evaluate strategic options for its original biotechnology platform derived from the research of Professor Luigi Naldini
Focused on selective acquisitions of high-quality companies in strategic industrial sectors <pre>Focused on selective acquisitions of high-quality com
Mar 13, 2026
leadership
Genenta, Evolving into Saentra Forge, Announces CEO’s Appointment by the Italian Government to the Board of Guarantors of the Italian Academy at Columbia University
Genenta, Evolving into Saentra Forge, Announces CEO’s Appointment to the Board of Guarantors of the Italian Academy at Columbia University